Cliff Asness's TGTX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 67,811 shares of TG Therapeutics, Inc. (TGTX) worth $2.45 M, representing 0.00% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in TGTX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2017, adding 36,263 shares. Largest reduction occurred in Q2 2017, reducing 42,849 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +10,200 | New Buy | 10,200 | $5.10 |
| Q4 2013 | +32,900 | Add 322.55% | 43,100 | $3.90 |
| Q2 2014 | -25,600 | Reduce 59.40% | 17,500 | $9.37 |
| Q3 2014 | +11,400 | Add 65.14% | 28,900 | $10.66 |
| Q4 2014 | +19,500 | Add 67.47% | 48,400 | $15.85 |
| Q1 2015 | +1,100 | Add 2.27% | 49,500 | $15.47 |
| Q2 2015 | +13,560 | Add 27.39% | 63,060 | $16.59 |
| Q3 2015 | -9,937 | Reduce 15.76% | 53,123 | $10.07 |
| Q4 2015 | -53,123 | Sold Out | 53,123 | $0.00 |
| Q2 2017 | +10,274 | New Buy | 10,274 | $10.03 |
| Q3 2017 | +36,263 | Add 352.96% | 46,537 | $11.84 |
| Q1 2018 | +730 | Add 1.57% | 47,267 | $14.20 |
| Q2 2018 | -11,483 | Reduce 24.29% | 35,784 | $13.16 |
| Q3 2018 | -18,836 | Reduce 52.64% | 16,948 | $5.61 |
| Q4 2018 | -16,948 | Sold Out | 16,948 | $0.00 |
| Q4 2019 | +36,171 | New Buy | 36,171 | $11.09 |
| Q1 2020 | +8,624 | Add 23.84% | 44,795 | $9.84 |
| Q2 2020 | +24,075 | Add 53.74% | 68,870 | $19.49 |
| Q3 2020 | +7,898 | Add 11.47% | 76,768 | $26.76 |
| Q4 2020 | -5,012 | Reduce 6.53% | 71,756 | $52.02 |
| Q1 2021 | -9,148 | Reduce 12.75% | 62,608 | $48.20 |
| Q3 2021 | -12,173 | Reduce 19.44% | 50,435 | $33.27 |
| Q4 2021 | -16,354 | Reduce 32.43% | 34,081 | $19.01 |
| Q2 2022 | -34,081 | Sold Out | 34,081 | $0.00 |
| Q1 2023 | +43,377 | New Buy | 43,377 | $15.04 |
| Q2 2023 | +20,261 | Add 46.71% | 63,638 | $24.84 |
| Q3 2023 | -3,783 | Reduce 5.94% | 59,855 | $8.36 |
| Q4 2023 | -41,968 | Reduce 70.12% | 17,887 | $17.08 |
| Q1 2024 | +26,477 | Add 148.02% | 44,364 | $15.21 |
| Q2 2024 | -6,339 | Reduce 14.29% | 38,025 | $17.79 |
| Q3 2024 | +21,411 | Add 56.31% | 59,436 | $23.39 |
| Q4 2024 | +8,431 | Add 14.19% | 67,867 | $30.10 |
| Q1 2025 | -32,574 | Reduce 48.00% | 35,293 | $39.43 |
| Q2 2025 | -1,944 | Reduce 5.51% | 33,349 | $35.99 |
| Q3 2025 | +34,462 | Add 103.34% | 67,811 | $36.13 |
Cliff Asness's TG Therapeutics Investment FAQs
Cliff Asness first purchased TG Therapeutics, Inc. (TGTX) in Q3 2013, acquiring 10,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held TG Therapeutics, Inc. (TGTX) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to TG Therapeutics, Inc. (TGTX) was in Q1 2023, adding 43,377 shares worth $652,390. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 67,811 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $2.45 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in TG Therapeutics, Inc. (TGTX) was 76,768 shares, as reported at the end of Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.